Abstract:
Background: Studies of the cardiovascular system are not included in the examination protocol in children with asthma, that’s why cardiac pathology
in these patients is not diagnosed on time. Late diagnosis of complications from cardiovascular system in children with bronchial asthma, inadequate
assessment of their prognosis and absence of cardiotropic therapy causes the high incidence.
Material and methods: We examined 189 children with persistent asthma aged 6 to 17 and 30 apparently healthy children who were in the control
group. In order to evaluate the effectiveness of the protective action of metabolic correctors in conjunction with combined drugs of basic therapy, we assessed
the presence of complaints from cardiovascular system, changes of electrocardiography data, blood electrolyte levels and markers of myocardial damage.
Results: Against the background of the complex therapy in combination with symbicort and ritmocor within 3 months was significantly less compared
to other treatment groups, met the clinical symptoms such as palpitations, a feeling of ‘intermittence of the heart’, weakness, decrease of the frequency of
sinus tachycardia, supraventricular arrhythmia, prolongation of the QT interval. These modifications were associated with increased levels of potassium
in the blood serum and erythrocytes. Differentiated treatment with symbicort, in conjunction with thiotriazoline, reduced sinus bradycardia and level
of myocardial damage markers.
Conclusions: Based on metabolic state modifications, myocardial correctors (ritmocor and thiotriazoline) in conjunction with base treatment have
proved their cardioprotective capacities in school-age children with uncontrollable bronchial asthma.
